Literature DB >> 20734220

Overexpression of PPARγ can down-regulate Skp2 expression in MDA-MB-231 breast tumor cells.

Jie Meng1, Yun Ding, Aiguo Shen, Meijuan Yan, Fei He, Huoyan Ji, Lin Zou, Yonghua Liu, You Wang, Xiaowei Lu, Huimin Wang.   

Abstract

Skp2 is frequent amplified and overexpressed in breast cancer, making it a potential molecular target for cancer therapy. The objective of this study was to examine the effect of PPARγ overexpression on Skp2 expression in breast cancer cell lines. First, we investigated the role of PPARγ and Skp2 in human breast cancer progression. Immunohistochemical analysis of 70 specimens on formalin-fixed paraffin sections was performed. Furthermore in vitro, Western blot analysis was used to study the relationship between PPARγ and Skp2. We found that the expression of PPARγ and Skp2 expression was inverse correlation whether in vivo or in vitro. In addition, PPARγ overexpression can down-regulate the expression of Skp2 mRNA and protein in breast cancer cells. PPARγ overexpression decreased breast cancer cell proliferation and induced spontaneous apoptosis even in the absence of exogenous ligand. These PPARγ-overexpressing cells were dramatically more sensitive to PPARγ ligand-induced apoptosis compared with parental or Myc-control transfected cells. Overexpressing of Skp2 partially reversed PPARγ's pro-apoptotic and anti-proliferative abilities. These results suggested that PPARγ's pro-apoptotic and anti-proliferative abilities appear to be triggered at least in part by the modulation of Skp2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20734220     DOI: 10.1007/s11010-010-0570-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

Review 2.  The many faces of PPARgamma.

Authors:  Michael Lehrke; Mitchell A Lazar
Journal:  Cell       Date:  2005-12-16       Impact factor: 41.582

3.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

4.  Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.

Authors:  Hironori Koga; Masaru Harada; Motoaki Ohtsubo; Shoichiro Shishido; Hiroto Kumemura; Shinichiro Hanada; Eitaro Taniguchi; Katsumi Yamashita; Ryukichi Kumashiro; Takato Ueno; Michio Sata
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

5.  Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells.

Authors:  Tatiana M Garcia-Bates; Steven H Bernstein; Richard P Phipps
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

6.  p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.

Authors:  A Ravaioli; F Monti; M M Regan; F Maffini; M G Mastropasqua; V Spataro; M Castiglione-Gertsch; I Panzini; L Gianni; A Goldhirsch; A Coates; K N Price; B A Gusterson; G Viale
Journal:  Ann Oncol       Date:  2008-02-13       Impact factor: 32.976

Review 7.  PPARgamma, an X-ceptor for Xs.

Authors:  Hana Koutnikova; Johan Auwerx
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

8.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.

Authors:  S A Kliewer; B M Forman; B Blumberg; E S Ong; U Borgmeyer; D J Mangelsdorf; K Umesono; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes.

Authors:  Chunhua Qin; Derek Morrow; Jessica Stewart; Kyle Spencer; Weston Porter; Roger Smith; Timothy Phillips; Maen Abdelrahim; Ismael Samudio; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

Review 10.  The nuclear receptor superfamily: the second decade.

Authors:  D J Mangelsdorf; C Thummel; M Beato; P Herrlich; G Schütz; K Umesono; B Blumberg; P Kastner; M Mark; P Chambon; R M Evans
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

View more
  7 in total

Review 1.  Skp2: a novel potential therapeutic target for prostate cancer.

Authors:  Zhiwei Wang; Daming Gao; Hidefumi Fukushima; Hiroyuki Inuzuka; Pengda Liu; Lixin Wan; Fazlul H Sarkar; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2011-09-22

Review 2.  Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Authors:  Gareth Chin Khye Ang; Amogh Gupta; Uttam Surana; Shirlyn Xue Ling Yap; Reshma Taneja
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

3.  Skp2 is a promising therapeutic target in breast cancer.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Hiroyuki Inuzuka; Lixin Wan; Pengda Liu; Daming Gao; Fazlul H Sarkar; Wenyi Wei
Journal:  Front Oncol       Date:  2012-01-04       Impact factor: 6.244

4.  Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.

Authors:  Sin-Ting Wang; Hsiu J Ho; Jaw-Town Lin; Jeng-Jer Shieh; Chun-Ying Wu
Journal:  Cell Death Dis       Date:  2017-02-23       Impact factor: 8.469

Review 5.  The Skp2 Pathway: A Critical Target for Cancer Therapy.

Authors:  Zhen Cai; Asad Moten; Danni Peng; Che-Chia Hsu; Bo-Syong Pan; Rajeshkumar Manne; Hong-Yu Li; Hui-Kuan Lin
Journal:  Semin Cancer Biol       Date:  2020-02-01       Impact factor: 17.012

6.  Skp2 regulates subcellular localization of PPARγ by MEK signaling pathways in human breast cancer.

Authors:  Hongge Cheng; Jie Meng; Guisheng Wang; Yuming Meng; Yu Li; Dong Wei; Chunyun Fu; Kaifeng Deng; Aiguo Shen; Huimin Wang; Shengming Dai
Journal:  Int J Mol Sci       Date:  2013-08-09       Impact factor: 5.923

7.  E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma.

Authors:  Jing Wang; Ying Huang; Zhong Guan; Jia-Liang Zhang; Hong-Kai Su; Wei Zhang; Cai-Feng Yue; Min Yan; Su Guan; Quentin Qiang Liu
Journal:  Oncotarget       Date:  2014-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.